Detailed performance report for NEOGENOMICS covering Q3 2025. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: NeoGenomics reported strong financial results for the third quarter of 2025, with total revenue of $188 million, reflecting a 12% year-over-year increase. The clinical business demonstrated robust growth, with a 15% revenue increase excluding the Pathline acquisition. Adjusted EBITDA was $12.2 million, marking the ninth consecutive quarter of positive earnings. Clinical test volumes rose by 15%, with average revenue per test increasing by 3% from the prior year.
Company Outlook & Strategy: NeoGenomics reiterated its full-year guidance, projecting consolidated revenue between $720 million and $726 million, representing 9% to 10% growth over 2024. The company anticipates adjusted EBITDA of $41 million to $44 million and expects to release its 2026 guidance in February 2026. NeoGenomics plans to continue expanding its presence in the community oncology setting and is optimistic about the growth potential of its NGS and MRD initiatives.
Key Industry Trends: The market for cancer testing continues to grow rapidly, with the therapy selection and MRD markets representing over $40 billion in addressable market opportunity. NeoGenomics is focusing on underpenetrated areas such as MRD, which is expected to grow at a 30% CAGR. The company is well-positioned to capture market share as it expands its test menu and enhances customer experience.
Operational Highlights: NeoGenomics is advancing its NGS and MRD initiatives, securing a favorable court ruling against Natera, which allows for the full clinical launch of its RaDaR ST MRD assay. The acquisition of Pathline has strengthened NeoGenomics' presence in the Northeast, enabling faster test turnaround times and operational efficiencies. The company's PanTracer LBx liquid biopsy test was launched in late July following an evaluation assessment program.
Challenges & Risks: The company faces challenges in its nonclinical business, which accounted for less than 9% of total revenue and experienced a decline due to reduced pharma and biotech customer revenue. Additionally, obtaining commercial reimbursement for new tests like RaDaR ST remains a challenge that could impact future financial performance.
Key Analyst Questions & Responses: Analysts inquired about the company's confidence in meeting guidance, the timeline for MRD reimbursement, and strategies to revitalize pharma business growth. NeoGenomics expressed confidence in achieving its guidance without relying on PanTracer liquid biopsy approval. The company anticipates a slow revenue build for RaDaR ST in pharma, with more significant contributions expected in the latter half of 2026. The sales force expansion is expected to support continued growth into next year.
Access the official earnings call transcript for NEOGENOMICS 2025 Q3. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.